Skip to main content
. 2017 Oct 20;25(1):29–39. doi: 10.1177/2047487317736827

Figure 3.

Figure 3.

Spectrograms of heart rate variability (HRV) in cardiomyopathy induced by doxorubicin (right). Note the reduction of HRV in lower frequencies (marked in red) by toxic doses of doxorubicin three days before fatal outcome. Source: reproduced with permission of D. Bajić.